Editorial
doi: 10.1111/j.1600-6143.2010.03026.x.
Belatacept: the promises and challenges of belatacept and costimulatory blockade
- PMID: 20415895
- DOI: 10.1111/j.1600-6143.2010.03026.x
Item in Clipboard
Editorial
Belatacept: the promises and challenges of belatacept and costimulatory blockade
Am J Transplant.
2010 Mar.
Free article
Abstract
The publication of the belatacept phase III studies offers a challenge in balancing benefits such as reduced burden of toxicity against risks such as EBV complications and more T cell mediated rejection.
Comment on
-
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Clinical Trial.
-
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x. Am J Transplant. 2010. PMID: 20415898 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
